Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
Identifieur interne : 000492 ( PubMed/Curation ); précédent : 000491; suivant : 000493Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
Auteurs : Salome Charalambous [Afrique du Sud] ; Alison D. Grant ; Craig Innes ; Christopher J. Hoffmann ; Rob Dowdeswell ; Jan Pienaar ; Katherine L. Fielding ; Gavin J. ChurchyardSource :
- AIDS (London, England) [ 1473-5571 ] ; 2010.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antituberculeux (usage thérapeutique), Charge virale, Facteurs de risque, Femelle, Humains, Incidence, Infections à VIH (), Infections à VIH (mortalité), Infections à VIH (traitement médicamenteux), Isoniazide (usage thérapeutique), Lieu de travail, Modèles de hasards proportionnels, Mâle, Numération des lymphocytes CD4, République d'Afrique du Sud (épidémiologie), Thérapie antirétrovirale hautement active (mortalité), Tuberculose (), Tuberculose (mortalité), Tuberculose (traitement médicamenteux), VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- MESH :
- mortalité : Infections à VIH, Thérapie antirétrovirale hautement active, Tuberculose.
- traitement médicamenteux : Infections à VIH, Tuberculose.
- usage thérapeutique : Antituberculeux, Isoniazide.
- épidémiologie : République d'Afrique du Sud.
- Adulte d'âge moyen, Charge virale, Facteurs de risque, Femelle, Humains, Incidence, Infections à VIH, Lieu de travail, Modèles de hasards proportionnels, Mâle, Numération des lymphocytes CD4, Tuberculose, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- Wicri :
- geographic : Afrique du Sud.
English descriptors
- KwdEn :
- Antiretroviral Therapy, Highly Active (mortality), Antitubercular Agents (therapeutic use), CD4 Lymphocyte Count, Female, HIV Infections (drug therapy), HIV Infections (mortality), HIV Infections (prevention & control), HIV-1, Humans, Incidence, Isoniazid (therapeutic use), Male, Middle Aged, Proportional Hazards Models, Risk Factors, South Africa (epidemiology), Tuberculosis (drug therapy), Tuberculosis (mortality), Tuberculosis (prevention & control), Viral Load, Workplace.
- MESH :
- chemical , therapeutic use : Antitubercular Agents, Isoniazid.
- geographic , epidemiology : South Africa.
- drug therapy : HIV Infections, Tuberculosis.
- mortality : Antiretroviral Therapy, Highly Active, HIV Infections, Tuberculosis.
- prevention & control : HIV Infections, Tuberculosis.
- CD4 Lymphocyte Count, Female, HIV-1, Humans, Incidence, Male, Middle Aged, Proportional Hazards Models, Risk Factors, Viral Load, Workplace.
Abstract
To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high.
DOI: 10.1097/01.aids.0000391010.02774.6f
PubMed: 21079429
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000492
Links to Exploration step
pubmed:21079429Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.</title><author><name sortKey="Charalambous, Salome" sort="Charalambous, Salome" uniqKey="Charalambous S" first="Salome" last="Charalambous">Salome Charalambous</name><affiliation wicri:level="1"><nlm:affiliation>The Aurum Institute, Johannesburg, South Africa. salomec@auruminstitute.org</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>The Aurum Institute, Johannesburg</wicri:regionArea></affiliation></author><author><name sortKey="Grant, Alison D" sort="Grant, Alison D" uniqKey="Grant A" first="Alison D" last="Grant">Alison D. Grant</name></author><author><name sortKey="Innes, Craig" sort="Innes, Craig" uniqKey="Innes C" first="Craig" last="Innes">Craig Innes</name></author><author><name sortKey="Hoffmann, Christopher J" sort="Hoffmann, Christopher J" uniqKey="Hoffmann C" first="Christopher J" last="Hoffmann">Christopher J. Hoffmann</name></author><author><name sortKey="Dowdeswell, Rob" sort="Dowdeswell, Rob" uniqKey="Dowdeswell R" first="Rob" last="Dowdeswell">Rob Dowdeswell</name></author><author><name sortKey="Pienaar, Jan" sort="Pienaar, Jan" uniqKey="Pienaar J" first="Jan" last="Pienaar">Jan Pienaar</name></author><author><name sortKey="Fielding, Katherine L" sort="Fielding, Katherine L" uniqKey="Fielding K" first="Katherine L" last="Fielding">Katherine L. Fielding</name></author><author><name sortKey="Churchyard, Gavin J" sort="Churchyard, Gavin J" uniqKey="Churchyard G" first="Gavin J" last="Churchyard">Gavin J. Churchyard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:21079429</idno><idno type="pmid">21079429</idno><idno type="doi">10.1097/01.aids.0000391010.02774.6f</idno><idno type="wicri:Area/PubMed/Corpus">000492</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000492</idno><idno type="wicri:Area/PubMed/Curation">000492</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000492</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.</title><author><name sortKey="Charalambous, Salome" sort="Charalambous, Salome" uniqKey="Charalambous S" first="Salome" last="Charalambous">Salome Charalambous</name><affiliation wicri:level="1"><nlm:affiliation>The Aurum Institute, Johannesburg, South Africa. salomec@auruminstitute.org</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>The Aurum Institute, Johannesburg</wicri:regionArea></affiliation></author><author><name sortKey="Grant, Alison D" sort="Grant, Alison D" uniqKey="Grant A" first="Alison D" last="Grant">Alison D. Grant</name></author><author><name sortKey="Innes, Craig" sort="Innes, Craig" uniqKey="Innes C" first="Craig" last="Innes">Craig Innes</name></author><author><name sortKey="Hoffmann, Christopher J" sort="Hoffmann, Christopher J" uniqKey="Hoffmann C" first="Christopher J" last="Hoffmann">Christopher J. Hoffmann</name></author><author><name sortKey="Dowdeswell, Rob" sort="Dowdeswell, Rob" uniqKey="Dowdeswell R" first="Rob" last="Dowdeswell">Rob Dowdeswell</name></author><author><name sortKey="Pienaar, Jan" sort="Pienaar, Jan" uniqKey="Pienaar J" first="Jan" last="Pienaar">Jan Pienaar</name></author><author><name sortKey="Fielding, Katherine L" sort="Fielding, Katherine L" uniqKey="Fielding K" first="Katherine L" last="Fielding">Katherine L. Fielding</name></author><author><name sortKey="Churchyard, Gavin J" sort="Churchyard, Gavin J" uniqKey="Churchyard G" first="Gavin J" last="Churchyard">Gavin J. Churchyard</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiretroviral Therapy, Highly Active (mortality)</term><term>Antitubercular Agents (therapeutic use)</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (mortality)</term><term>HIV Infections (prevention & control)</term><term>HIV-1</term><term>Humans</term><term>Incidence</term><term>Isoniazid (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Risk Factors</term><term>South Africa (epidemiology)</term><term>Tuberculosis (drug therapy)</term><term>Tuberculosis (mortality)</term><term>Tuberculosis (prevention & control)</term><term>Viral Load</term><term>Workplace</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antituberculeux (usage thérapeutique)</term><term>Charge virale</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Infections à VIH ()</term><term>Infections à VIH (mortalité)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Isoniazide (usage thérapeutique)</term><term>Lieu de travail</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>République d'Afrique du Sud (épidémiologie)</term><term>Thérapie antirétrovirale hautement active (mortalité)</term><term>Tuberculose ()</term><term>Tuberculose (mortalité)</term><term>Tuberculose (traitement médicamenteux)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antitubercular Agents</term><term>Isoniazid</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à VIH</term><term>Thérapie antirétrovirale hautement active</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term><term>Tuberculose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antituberculeux</term><term>Isoniazide</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>République d'Afrique du Sud</term></keywords><keywords scheme="MESH" xml:lang="en"><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV-1</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Risk Factors</term><term>Viral Load</term><term>Workplace</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Charge virale</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Infections à VIH</term><term>Lieu de travail</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Tuberculose</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique du Sud</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21079429</PMID><DateCreated><Year>2010</Year><Month>11</Month><Day>16</Day></DateCreated><DateCompleted><Year>2011</Year><Month>03</Month><Day>25</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>24 Suppl 5</Volume><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.</ArticleTitle><Pagination><MedlinePgn>S5-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/01.aids.0000391010.02774.6f</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ART-naive individuals starting ART from January 2004 to December 2007 were followed for up to 12 months. Deaths were ascertained from clinic and human resource data. The association between IPT and mortality was assessed using Cox regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3270 individuals were included (median age 45; 93% men; median baseline CD4 cell count 155 cells/μl (interquartile range 87-221); and 45% with WHO stage 3/4]. Nine hundred twenty-two (28%) individuals started IPT either prior to or within 3 months of starting ART. Individuals who started IPT tended to have less advanced HIV disease at ART initiation. Two hundred fifty-nine (7.9%) deaths were observed with overall mortality rate 8.9 per 100 person-years [95% confidence interval (CI) 7.9-10.6]. The unadjusted mortality rate was lower among those who received IPT compared with those who did not [3.7/100 vs. 11.1/100 person-years, respectively, hazard ratio 0.34 (95% CI 0.24-0.49)]; this association remained after adjustment for age, baseline CD4 cell count, baseline WHO stage, year of ART start, and individual company (hazard ratio 0.51, 95% CI 0.32-0.80). In sensitivity analyses restricted to those with no previous history of TB (n = 3036) or with no TB symptoms at ART initiation (n = 2251), IPT remained associated with reduced mortality [adjusted hazard ratios 0.51 (95% CI 0.32-0.81) and 0.48 (95% CI 0.24-0.96), respectively].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Mortality was lower among individuals receiving IPT with or prior to ART start. These results support routine use of IPT in conjunction with ART.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charalambous</LastName><ForeName>Salome</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Aurum Institute, Johannesburg, South Africa. salomec@auruminstitute.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Alison D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Innes</LastName><ForeName>Craig</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Dowdeswell</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pienaar</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fielding</LastName><ForeName>Katherine L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Churchyard</LastName><ForeName>Gavin J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DK074348</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 DK074348</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI083099</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI016137</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>AI016137</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI5535901</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI016137</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>V83O1VOZ8L</RegistryNumber><NameOfSubstance UI="D007538">Isoniazid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1998 Dec 24;12(18):2447-57</RefSource><PMID Version="1">9875583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Mar 11;13(4):501-7</RefSource><PMID Version="1">10197379</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2005 Jun 8;293(22):2719-25</RefSource><PMID Version="1">15941800</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Dec 2;19(18):2109-16</RefSource><PMID Version="1">16284460</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Dec 2;19(18):2141-8</RefSource><PMID Version="1">16284464</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Southeast Asian J Trop Med Public Health. 2005 Sep;36(5):1208-15</RefSource><PMID Version="1">16438147</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Mar 11;367(9513):817-24</RefSource><PMID Version="1">16530575</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2006 Aug 1;20(12):1605-12</RefSource><PMID Version="1">16868441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2006 Sep 15;43(6):770-6</RefSource><PMID Version="1">16912954</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2007 Jan;19(1):34-41</RefSource><PMID Version="1">17129856</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Jul 11;21(11):1441-8</RefSource><PMID Version="1">17589190</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2007 Aug 15;196 Suppl 1:S52-62</RefSource><PMID Version="1">17624827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2007 Nov;11(11):1232-6</RefSource><PMID Version="1">17958987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2007 Nov;21 Suppl 6:S97-S104</RefSource><PMID Version="1">18032945</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2008 Jul;12(7):769-72</RefSource><PMID Version="1">18544202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Oct 1;22(15):1897-908</RefSource><PMID Version="1">18784453</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Mar 13;23(5):631-6</RefSource><PMID Version="1">19525621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin HIV AIDS. 2009 Jul;4(4):325-33</RefSource><PMID Version="1">19532072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Jul 17;23(11):1446-7</RefSource><PMID Version="1">19564725</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2010;(1):CD000171</RefSource><PMID Version="1">20091503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2010 Jul;10(7):489-98</RefSource><PMID Version="1">20610331</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Nov;24 Suppl 5:S45-8</RefSource><PMID Version="1">21079427</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Nov 9;15(16):2137-47</RefSource><PMID Version="1">11684933</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2002 May 1;34(9):1251-8</RefSource><PMID Version="1">11941552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Jun 15;359(9323):2059-64</RefSource><PMID Version="1">12086758</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2004;(1):CD000171</RefSource><PMID Version="1">14973947</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1993 Dec;7(12):1569-79</RefSource><PMID Version="1">7904450</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1997 Jun;11(7):875-82</RefSource><PMID Version="1">9189212</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1997 Sep 18;337(12):801-8</RefSource><PMID Version="1">9295239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1997;11 Suppl B:S43-54</RefSource><PMID Version="1">9416366</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>AIDS. 2011 Jul 31;25(12):1554-5; author reply 1556</RefSource><PMID Version="1">21747238</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>AIDS. 2010 Nov;24 Suppl 5:S15-8</RefSource><PMID Version="1">21079423</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007538" MajorTopicYN="N">Isoniazid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017132" MajorTopicYN="N">Workplace</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS477231</OtherID><OtherID Source="NLM">PMC3724406</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21079429</ArticleId><ArticleId IdType="doi">10.1097/01.aids.0000391010.02774.6f</ArticleId><ArticleId IdType="pii">00002030-201011005-00002</ArticleId><ArticleId IdType="pmc">PMC3724406</ArticleId><ArticleId IdType="mid">NIHMS477231</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000492 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000492 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21079429
|texte= Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21079429" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |